Unapproved Retatrutide Bought Online: What Three New Journal Articles Report

Headline Check · Reviewed by Thomas Okafor, Peptide Chemist · Published October 16, 2026

Retatrutide has had a big year in the trial literature, with three phase 3 readouts and a Lancet commentary on its diabetes trial published October 10. Lilly plans to file it with FDA in early 2027. Meanwhile, products labeled as retatrutide are already being sold online, often as “research use only,” which is where these three articles come in.

1. What Reddit users describe: JAMA Network Open

Observational (social media analysis)

University of Pennsylvania researchers analyzed 148,640 retatrutide-related Reddit posts and comments from 38,936 users across 27 communities, using a language model to pull out reported symptoms [1]. Among 7,823 users who described current use and mentioned at least one symptom, the most common terms were increased appetite (17.1%), fatigue (15.2%), increased energy (12.4%) and nausea (11.6%). Insomnia (6.1%) and increased heart rate (4.8%) also appeared.

The authors noted that gastrointestinal symptoms were common but less dominant than in trials of approved GLP-1 drugs, and suggested, speculatively, that retatrutide’s glucagon activity might play a role [1].

What it can’t show: product identity, purity and amounts couldn’t be verified, Reddit posters aren’t representative, and the design can’t measure how often effects occur or whether the product caused them. The authors call the findings hypothesis-generating [1].

2. What testing and enforcement show: JAMA

News report

A JAMA Medical News report described a fast-growing black market for retatrutide and zenagamtide, Novo Nordisk’s investigational GLP-1 and amylin agonist [2]. Points it highlighted:

• Wrong contents. Australia’s drug regulator tested a product labeled retatrutide after a serious adverse event and found semaglutide instead, at a high amount.
• Wrong amounts. University of Queensland researchers tested three products labeled 10 mg. All contained retatrutide, but one held about half the stated amount and two held more.
• Hospitalizations. Public Citizen counted at least 14 hospitalizations linked to black-market retatrutide in FDA’s adverse event database.
• Enforcement. FDA has issued 21 warning letters to retatrutide sellers since December 2024, and Lilly filed six lawsuits against sellers in August.

“It is digital-age bootlegging,” Peter Pitts, a former FDA associate commissioner, told JAMA [2].

3. A hospital case: BMJ Case Reports

Single case report

Physicians at University Hospital Zurich described a woman in her mid-20s admitted with five days of persistent nausea and vomiting [3]. Tests found no other cause. She had received injections of an unverified product reported to contain retatrutide in a wellness setting, from someone without medical qualifications, and didn’t consider them medication. Symptoms resolved within a week. The authors rated the link as probable and urged clinicians to ask directly about peptides, research chemicals and online products [3].

What the three articles add up to

These articles don’t measure risk across a population, and a single case can’t. What they do show, consistently, is the problem every research-use-only buyer faces: without verified testing, a vial’s label and its contents can differ. The FDA warning letters we covered last week made the same point from the enforcement side.

For context, see our report on FDA warning letters to research-use-only peptide sellers and our guide to verifying a peptide COA.

Retatrutide isn’t FDA-approved, and products sold online aren’t the drug tested in Lilly’s trials. This article is for education only and isn’t medical advice.